Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: neurodegenerative disorders therapeutics - BioArctic Neuroscience

Drug Profile

Research programme: neurodegenerative disorders therapeutics - BioArctic Neuroscience

Alternative Names: AD 1503; AD-0802; AD-1502; AD-2203; AE-1501; BAN-2203; BAN-2502; BAN2401 back-up; PD 1601; PD 1602

Latest Information Update: 20 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioArctic Neuroscience
  • Developer BioArctic
  • Class Antidementias; Antiparkinsonians; Monoclonal antibodies; Vaccines
  • Mechanism of Action Alpha-synuclein inhibitors; Amyloid beta-protein inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease
  • Research Parkinson's disease

Most Recent Events

  • 03 Sep 2018 BioArctic and Uppsala University expand research collaboration for antibody-based diagnostic PET ligands
  • 07 Aug 2018 BioArctic obtains exclusive rights within its collaboration with Eisai to develop antibodies for Alzheimer's disease
  • 14 May 2018 BioArctic and Uppsala University extends research collaboration for antibody technology to increase passage across the blood-brain barrier for neurodegenerative diseases
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top